businesspress24.com - Aurora Announces Completion of Pre-License Assessments by Health Canada, Receipt of Production Licen
 

Aurora Announces Completion of Pre-License Assessments by Health Canada, Receipt of Production License for Building Number 3 and other Updates

ID: 1389268

(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 10/01/15 -- Aurora Cannabis Inc. (CSE: ACB)(FRANKFURT: 21P)(WKN: A1C4WM)(OTCQB: ACBFF) ("Aurora" or the "Company") is pleased to announce that on Friday, September 25, 2015, Health Canada inspectors from the Regions and Programs Bureau ("RAPB") completed their latest assessments in response to three active section 29 license amendment applications. The assessment visit commenced on September 22, 2015.

On the same day, Aurora received approval for its Building Number 3 Production license under the Marihuana for Medical Purposes Regulations ("MMPR"). Aurora''s entire facility is now approved to produce dried medical cannabis.

Aurora anticipates receiving further news regarding the additional section 29 license amendment applications including the Cannabis Oil Production License and the Sale of Dried Marijuana License.

Terry Booth, CEO, commented: "Getting the building 3 confirmation so quickly after the inspection is a fantastic sign. We are looking forward to the issuance of our sales license and extraction license so we can provide Canadians high quality medical cannabis produced to the Aurora Standard."

Australis Holdings LLP, a 50% subsidiary of Aurora, continues with the engineering and design on the Bellingham project. The preliminary drawings have been received and are being reviewed. Washington regulators announced plans to begin Phase 2 of their medical cannabis program including to once again accept license applications on October 12, 2015, for the first time since 2012.

About Aurora Cannabis Inc.

Aurora''s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada. Aurora''s wholly-owned subsidiary, Australis Capital Inc., seeks to be an active participant in the U.S. Cannabis market. Aurora is trading on the Canadian Securities Exchange under the trading symbol "ACB".





On behalf of the Board of Directors,

AURORA CANNABIS INC.

Terry Booth, CEO

The CSE, securities commission or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.



Contacts:
Aurora Cannabis Inc.
Nilda Rivera
Investor Relations
Toll Free: 1-844-928-7672


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Penis Enlargement Bible Review | How To Make Your Penis Bigger Naturally Without Pills - Apennyblog.com
Stellar Biotechnologies and Amaran Biotechnology Provide Update on Collaboration
Bereitgestellt von Benutzer: Marketwired
Datum: 01.10.2015 - 04:30 Uhr
Sprache: Deutsch
News-ID 1389268
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

VANCOUVER, BRITISH COLUMBIA


Phone:

Kategorie:

Healthcare


Anmerkungen:


Diese Pressemitteilung wurde bisher 185 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Aurora Announces Completion of Pre-License Assessments by Health Canada, Receipt of Production License for Building Number 3 and other Updates
"
steht unter der journalistisch-redaktionellen Verantwortung von

Aurora Cannabis Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Aurora Cannabis Inc.



 

Who is online

All members: 10 577
Register today: 3
Register yesterday: 0
Members online: 0
Guests online: 104


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.